Investigating the Role of Anti-TPO Antibodies in HIV-Associated Thrombocytopenia before and after Initiation of HAART: A Case-Control Longitudinal Study
2023
Aristotelis Tsiakalos | John G. Routsias | Georgios Schinas | Sarah Georgiadou | Nikolaos V. Sipsas | Karolina Akinosoglou
This longitudinal, case-control study aimed to investigate the role of thrombopoietin (TPO) and anti-TPO antibodies in HIV-associated thrombocytopenia, focusing on the changes seen before and after the initiation of highly active antiretroviral therapy (HAART). Patients were assessed before and at least six months after the initiation of HAART. In total, 75 PLWHIV (age/sex-matched and randomized at 2:1, according to thrombocytopenia status) were included in this study. The baseline assessment revealed significantly higher TPO levels in thrombocytopenic patients (140.45 vs. 106.8 mg/mL, <i>p</i> = 0.008). Furthermore, anti-TPO-positive patients displayed lower platelet counts (109,000 vs. 139,000/L, <i>p</i> = 0.002) and TPO levels (114.7 vs. 142.7 mg/mL, <i>p</i> = 0.047). Longitudinally, HAART initiation reduced the frequency of thrombocytopenia from 75.47% to 33.96% (<i>p</i> < 0.001) and elevated the median platelet counts from 131,000 to 199,000 (<i>p</i> < 0.001). No significant difference in median platelet counts was found post-HAART among the anti-TPO subgroups (<i>p</i> = 0.338), a result contrasting with pre-HAART findings (<i>p</i> = 0.043). Changes in anti-TPO status corresponded with significant platelet count alterations (<i>p</i> = 0.036). Notably, patients who became anti-TPO negative showed a median increase of 95,000 platelets (IQR: 43,750–199,500). These marked differences between subgroups underscore the potential role of anti-TPO antibodies in modulating the hematological response to HAART. Further research is needed to elucidate the complex interplay between HIV infection, HAART, and thrombocytopenia.
显示更多 [+] 显示较少 [-]